ClearPoint Neuro Balance Sheet Health
Financial Health criteria checks 6/6
ClearPoint Neuro has a total shareholder equity of $29.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $40.2M and $11.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$21.57m |
| Equity | US$29.00m |
| Total liabilities | US$11.19m |
| Total assets | US$40.19m |
Recent financial health updates
Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?
Aug 16
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Dec 06Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?
Aug 18Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Jan 03ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?
Aug 18Recent updates
After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
Dec 10Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%
Sep 14Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?
Aug 16Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%
Jul 11ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 09ClearPoint Neuro: Macro-Induced Multiple Compression
Apr 25Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?
Apr 19Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report
Mar 15Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?
Jan 04Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Dec 06Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?
Nov 06Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?
Aug 18ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump
Apr 17Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Jan 03ClearPoint Neuro: Continuous Great Execution
Sep 19ClearPoint Neuro: Picks & Shovels Galore
Aug 19ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?
Aug 18ClearPoint Neuro: A 'Picks And Shovels' Biotech Company
Jul 25ClearPoint Neuro: Continuous Execution Despite Covid Headwind
May 20Financial Position Analysis
Short Term Liabilities: CLPT's short term assets ($34.3M) exceed its short term liabilities ($7.6M).
Long Term Liabilities: CLPT's short term assets ($34.3M) exceed its long term liabilities ($3.6M).
Debt to Equity History and Analysis
Debt Level: CLPT is debt free.
Reducing Debt: CLPT has no debt compared to 5 years ago when its debt to equity ratio was 31.1%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CLPT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CLPT has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 22.1% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 07:51 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ClearPoint Neuro, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Kyle Bauser | B. Riley Securities, Inc. |
| Sally Yanchus | Brookline Capital Markets |